Latest news
Loading news…
CoImmune
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Durham, North Carolina, United States Founded 2019 11-50 employees For Profit
CoImmune is a cell therapy company designed to leverage your own immune system to fight disease.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
1
Monthly Visits
Available in Pro Contacts
30
Patents
20
2 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 10
- Patents granted
- 20
- Trademarks
- 2
- Top patent class
- Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering
- IT spend
- $403.45K
Company Info
- Founded
- 2019
- Employees
- 11-50
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- News articles
- 6
- HQ
- Durham, North Carolina, United States
- Region
- Research Triangle, East Coast, Southern US
Signals & Scores
- Heat score
- High
- Growth score
- Low
- Trend (7d)
- 0.2
- Trend (30d)
- 1.1
- Trend (90d)
- 1.9
Acquisitions by CoImmune
Loading columns…
0 of 0Show
Page 1 / 1
30
professional contacts at CoImmune
Contact execs at CoImmune →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to CoImmune
Loading news…
FAQs about CoImmune
People who checked this page also checked these
Browse the full Acquirezy directory.